4.5 Fetal Arrhythmias, Dysrhythmias & Artifact Differentiation

Electrophysiology and Classification of Fetal Arrhythmias

Fetal cardiac arrhythmias occur in approximately 1% to 2% of all pregnancies and account for 10% to 20% of referrals to maternal-fetal medicine specialists. While the vast majority represent benign, transient conduction delays, sustained fetal tachyarrhythmias and bradyarrhythmias can lead to cardiovascular collapse, non-immune hydrops fetalis, and intrauterine demise.

+-------------------------------------------------------------------------------------------------------------------+
|                                 CLASSIFICATION OF FETAL CARDIAC ARRHYTHMIAS                                       |
+-------------------------------------------------------------------------------------------------------------------+
                                                         |
         +-----------------------------------------------+-----------------------------------------------+
         |                                               |                                               |
         v                                               v                                               v
  [ IRREGULAR RHYTHMS ]                       [ TACHYARRHYTHMIAS ]                            [ BRADYARRHYTHMIAS ]
  - Premature Atrial Contractions             - Supraventricular Tachycardia (SVT)            - Complete (3rd Degree) AV Block
    (PACs / APCs) [>85% of cases]               (Rate 210 to 260+ bpm)                          (Ventricular rate 50-80 bpm)
  - Premature Ventricular Contractions        - Atrial Flutter                                - Sinus Bradycardia (<110 bpm)
    (PVCs / VPCs)                               (Atrial 300-500, Ventric 150-240)             - Blocked Atrial Bigeminy
  - Benign, self-limiting (>98%)              - Risk: Non-Immune Hydrops Fetalis              - Linked to maternal anti-Ro/SSA
+-------------------------------------------------------------------------------------------------------------------+

---

Irregular Fetal Rhythms: PACs and PVCs

Premature Atrial Contractions (PACs)

• Epidemiology & Electrophysiology: PACs (also called atrial premature beats) represent >85% to 90% of all diagnosed fetal arrhythmias. They originate from an irritable ectopic atrial pacemaker firing prematurely before the sinoatrial (SA) node discharges, reflecting electrophysiological immaturity of the developing conduction system.
• EFM Tracing Appearance: On continuous electronic fetal monitoring, PACs appear as sudden, sharp, vertical "spikes" shooting above the baseline (conducted PACs) or brief downward tick marks / drop-offs (blocked/non-conducted PACs). The underlying baseline FHR rate and baseline variability remain completely normal.
• Clinical Prognosis & Management: Over 98% of fetal PACs are benign and self-limiting, resolving spontaneously in the late third trimester or within the first 1 to 2 weeks of neonatal life. However, in 1% to 2% of cases, frequent PACs (especially atrial bigeminy or trigeminy) can trigger sustained re-entrant Supraventricular Tachycardia (SVT). Inpatient nursing care involves serial auscultation, monitoring for sustained rate acceleration, and avoidance of maternal caffeine and sympathomimetics.

Premature Ventricular Contractions (PVCs)

• Originates from an ectopic ventricular focus below the AV node. Characterized by an irregular rhythm with a fully compensatory pause. Less common than PACs and typically benign, but requires postnatal 12-lead ECG to rule out long QT syndrome or structural cardiomyopathy.

---

Fetal Tachyarrhythmias: SVT and Atrial Flutter

+-------------------------------------------------------------------------------------------------------------------+
|                                 FETAL TACHYARRHYTHMIA COMPARISON TABLE                                            |
+-------------------------------------------------------------------------------------------------------------------+
  Arrhythmia Type       Ventricular Rate Range    Rhythm & Variability Features       Hemodynamic Risks & Management
  --------------------  ------------------------  ----------------------------------  -------------------------------
  Supraventricular      210 to 260+ bpm           Abrupt, step-like onset & offset;   Loss of diastolic filling time;
  Tachycardia (SVT)     (Fixed, monotonous)       ABSENT baseline variability during  Non-Immune Hydrops; First-line:
                                                  paroxysms; 1:1 AV conduction        Digoxin, Flecainide, Sotalol
  --------------------  ------------------------  ----------------------------------  -------------------------------
  Atrial Flutter        150 to 240 bpm            Sawtooth atrial flutter waves on    High cardiac output failure;
                        (Atrial: 300 to 500 bpm)  echocardiography; 2:1 or 3:1 AV     Hydrops risk; First-line:
                                                  conduction block                    Sotalol or Flecainide
  --------------------  ------------------------  ----------------------------------  -------------------------------
  Sinus Tachycardia     161 to 180 (rarely >190)  Gradual onset & resolution;         Infection, fever, anemia, drug;
                                                  Preserved moderate variability      Treat underlying maternal cause
+-------------------------------------------------------------------------------------------------------------------+

Pathophysiology of Supraventricular Tachycardia (SVT) and Hydrops Fetalis

Sustained SVT (>50% of the monitoring time) is a life-threatening fetal cardiac emergency. At ventricular rates of 220 to 260 bpm:

1. Loss of Diastolic Ventricular Filling: Extreme tachycardia severely curtails the diastolic filling period of both ventricles, reducing end-diastolic volume and stroke volume.
2. Elevated Central Venous Pressure: Back-pressure into the right atrium, inferior vena cava, and hepatic veins produces marked systemic venous congestion and elevated capillary hydrostatic pressure.
3. Myocardial Ischemia: Diminished coronary arterial perfusion pressure combined with extreme myocardial oxygen demand leads to cardiac enlargement and progressive biventricular congestive heart failure.
4. Development of Non-Immune Hydrops Fetalis: Fluid extravasates into interstitial tissues and fetal body cavities, manifesting as pleural effusions, pericardial effusions, ascites, polyhydramnios, and scalp/skin edema (defined as fluid accumulation in >=2 fetal compartments).

+-------------------------------------------------------------------------------------------------------------------+
|                         PATHOPHYSIOLOGICAL CASCADE: SUSTAINED SVT TO HYDROPS FETALIS                              |
+-------------------------------------------------------------------------------------------------------------------+
  [ Sustained Fetal SVT (220-260 bpm) ]
                   |
                   v
  [ Shortened Diastolic Ventricular Filling Time ] ---> [ Decreased Cardiac Output & Stroke Volume ]
                   |
                   v
  [ Severe Systemic Venous Congestion & High CVP ] ---> [ Hepatic Congestion & Decreased Albumin Synthesis ]
                   |
                   v
  [ Capillary Hydrostatic Fluid Extravasation ]
                   |
                   v
  [ NON-IMMUNE HYDROPS FETALIS ] ---> (Pleural Effusions + Pericardial Effusion + Ascites + Scalp Edema)
                   |
                   v
  [ Intrauterine Fetal Demise / Severe Neonatal Compromise ]
+-------------------------------------------------------------------------------------------------------------------+

Transplacental Antiarrhythmic Pharmacotherapy

• Digoxin: Historically first-line agent. Increases myocardial vagal tone and slows AV nodal conduction. Crosses the placenta well in non-hydropic fetuses (maternal therapeutic serum level: 1.0 to 2.0 ng/mL). However, placental transfer is markedly impaired in hydropic fetuses.
• Flecainide: Class IC antiarrhythmic. Drug of choice for SVT with established hydrops fetalis due to superior transplacental penetration and high cardioversion rates (>80–90%).
• Sotalol: Class III beta-blocker/potassium-channel blocker. First-line agent for fetal Atrial Flutter.

---

Fetal Bradyarrhythmias: Complete Congenital Heart Block

Complete (Third-Degree) Atrioventricular Block (CAVB)

• Clinical Presentation: Persistent, fixed fetal heart rate between 50 and 80 bpm with complete dissociation between atrial and ventricular depolarizations on fetal echocardiography. The ventricular rate is completely unresponsive to maternal movement or uterine contractions.
• Autoimmune Etiology (Maternal Anti-Ro/SSA & Anti-La/SSB Antibodies):
  • In approximately 50% of cases, complete heart block is caused by transplacental transfer of maternal IgG autoantibodies (anti-Ro/SSA and anti-La/SSB) in mothers with Systemic Lupus Erythematosus (SLE), Sjögren's syndrome, or asymptomatic carriers.
  • Mechanism: Maternal IgG antibodies cross the placenta between 16 and 24 weeks of gestation, bind directly to L-type calcium channels in the fetal cardiac conduction system, and trigger autoimmune myocarditis, macrophage infiltration, irreversible calcification, and fibrotic destruction of the fetal AV node and bundle of His.
• Structural Etiology: The remaining 50% of cases are associated with major congenital structural cardiac malformations (e.g., L-transposition of the great arteries, atrioventricular septal defects).
• Management & Prognosis: Once complete third-degree heart block is established, it is permanent and irreversible. Maternal treatment with fluorinated corticosteroids (Dexamethasone 4 mg/day orally) is used in early/incomplete block to suppress autoimmune myocarditis. Ventricular rates <55 bpm or development of hydrops carries high mortality and requires immediate postnatal permanent cardiac pacemaker implantation.

EFM Artifact Differentiation and Signal Pitfalls

Inpatient obstetric nurses must possess expert skill in distinguishing true fetal cardiac dysrhythmias from electronic monitoring artifacts, equipment signal dropouts, and maternal signal transposition.

+-------------------------------------------------------------------------------------------------------------------+
|                         DIAGNOSTIC MATRIX: FETAL ARRHYTHMIAS VS. EFM ARTIFACTS                                    |
+-------------------------------------------------------------------------------------------------------------------+
  Pattern / Finding             Underlying Mechanism                  Distinguishing Features on Strip & Action
  ----------------------------  ------------------------------------  -----------------------------------------------
  Maternal Heart Rate (MHR)     Ultrasound transducer tracks maternal Rate is 70 to 100 bpm; shows acute accelerations
  Transposition                 iliac artery or aortic pulsation      coinciding exactly with contractions/pushing;
                                                                      Verify maternal pulse with pulse oximeter
  ----------------------------  ------------------------------------  -----------------------------------------------
  Double-Counting Artifact      Ultrasound machine counts both S1     Sudden jump from baseline (e.g., 75 bpm -> 150)
                                and S2 heart sounds or tall T-waves   No clinical distress; switch to FSE
  ----------------------------  ------------------------------------  -----------------------------------------------
  Half-Counting Artifact        Ultrasound machine fails to capture   True rate is severe tachycardia (e.g., 220 bpm)
                                every beat in rapid tachycardias      displayed as 110 bpm; auscultate heart rate stat
  ----------------------------  ------------------------------------  -----------------------------------------------
  Signal Dropout / Gap          Loss of acoustic ultrasound beam      Blank horizontal gaps in strip; adjust toco /
                                contact (maternal habitus/movement)   re-position transducer or place scalp electrode
+-------------------------------------------------------------------------------------------------------------------+

1. Maternal Heart Rate (MHR) Transposition

• Mechanism: The external Doppler ultrasound transducer inadvertently locks onto the pulsating maternal common iliac artery or descending aorta rather than the fetal heart.
• Classic Clinical Presentation: The tracing displays an apparent baseline rate between 70 and 100 bpm that exhibits sudden "accelerations" synchronized exactly with each uterine contraction or maternal pushing effort (as maternal heart rate spikes with exertion and pain). When the contraction ends, the heart rate drops back to 70–80 bpm, mimicking a profound deceleration.
• Nursing Confirmation: Immediately check the maternal radial pulse or place a continuous maternal pulse oximeter that integrates with the central EFM system. If the maternal pulse and the monitor rate match beat-for-beat, MHR transposition is confirmed.

2. Double-Counting and Half-Counting Artifacts

• Double-Counting: When the fetal heart rate is slow (bradycardia 60–80 bpm), the ultrasound machine may detect both the first heart sound (S1, mitral/tricuspid closure) and the second heart sound (S2, aortic/pulmonic closure) as separate cycles, displaying an artificial baseline of 120–160 bpm.
• Half-Counting: When the fetal heart rate is extremely rapid (SVT 220–260 bpm), the machine's processing algorithm may fail to register every alternating cycle, artificially displaying the rate at half its true value (e.g., 110–130 bpm).

3. Fetal Scalp Electrode (FSE / Spiral Electrode)

An internal fetal scalp electrode provides direct electrocardiographic (ECG) detection of the fetal R-to-R wave intervals, eliminating ultrasound acoustic artifact and providing true beat-to-beat variability measurement.

+-------------------------------------------------------------------------------------------------------------------+
|                         FETAL SCALP ELECTRODE (FSE) PREREQUISITES & CONTRAINDICATIONS                             |
+-------------------------------------------------------------------------------------------------------------------+
  MANDATORY CLINICAL PREREQUISITES:                           ABSOLUTE CLINICAL CONTRAINDICATIONS:
  1. Ruptured amniotic membranes (spontaneous or artificial)  1. Maternal HIV infection
  2. Adequate cervical dilation (at least 1 to 2 cm)          2. Active maternal Hepatitis B or Hepatitis C virus
  3. Accessible fetal presenting part                         3. Active maternal genital Herpes Simplex Virus (HSV)
  4. Confirmed cephalic presentation (avoid face, eyes,       4. Severe fetal bleeding diathesis (Hemophilia, vWD)
     fontanelles, or genitalia in breech)                     5. Unconfirmed presenting part or placenta previa
+-------------------------------------------------------------------------------------------------------------------+